Home › Glycogen Storage Disease Type II › Pennsylvania › Pittsburgh
Glycogen Storage Disease Type II clinical trials in Pittsburgh, PA
4 studies for Glycogen Storage Disease Type II are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
RecruitingPhase 1/2
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
RecruitingPhase 2
- University of Pittsburgh School of Medicine, Pittsburgh
Pompe Disease Registry Protocol
RecruitingObservational study
- UPMC Children's Hospital of Pittsburgh- Site Number : 840014, Pittsburgh
- UPMC Children's Hospital of Pittsburgh- Site Number : 840023, Pittsburgh
A Global Prospective Observational Registry of Patients With Pompe Disease
RecruitingObservational study
- University of Pittsburgh, Pittsburgh
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Glycogen Storage Disease Type II trials in other cities
- Durham, NC8 studies
- Irvine, CA5 studies
- St. Louis, MO5 studies
- Arlington, VA5 studies
- Philadelphia, PA4 studies
- New York City, NY4 studies
- Atlanta, GA4 studies
- Cincinnati, OH3 studies
- Jacksonville, FL3 studies
- Indianapolis, IN3 studies
- Phoenix, AZ3 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Prostate Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.